Reports how baseline T cell states and circulating immune signals predict T cell exhaustion and resistance to sustained CD3-engaging therapy in B-cell ALL.
Key Takeaways
- Blinatumomab (Blina) is a CD19xCD3 bispecific T cell engager that redirects CD3 + T cells towards CD19 + target cells
- It has been approved for the treatment of patients with Relapsed/Refractory (R/R)
- Primary resistance rates are close to 50% and 20% in the R/R and MRD + settings